Is GlaxoSmithKline PLC Stock a Good Investment?
GlaxoSmithKline PLC Investment Advice | GSK |
- Examine GlaxoSmithKline PLC's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research GlaxoSmithKline PLC's leadership team and their track record. Good management can help GlaxoSmithKline PLC navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact GlaxoSmithKline PLC's business and its evolving consumer preferences.
- Compare GlaxoSmithKline PLC's performance and market position to its competitors. Analyze how GlaxoSmithKline PLC is positioned in terms of product offerings, innovation, and market share.
- Check if GlaxoSmithKline PLC pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about GlaxoSmithKline PLC's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in GlaxoSmithKline PLC ADR stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if GlaxoSmithKline PLC ADR is a good investment.
Sell | Buy |
Strong Buy
Market Performance | Modest | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine GlaxoSmithKline PLC Stock
Researching GlaxoSmithKline PLC's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 15.0% of the company shares are owned by institutional investors. The book value of GlaxoSmithKline PLC was currently reported as 3.39. The company has Price/Earnings To Growth (PEG) ratio of 1.09. GlaxoSmithKline PLC ADR last dividend was issued on the 16th of May 2024. The entity had 1226:1000 split on the 22nd of July 2022.
To determine if GlaxoSmithKline PLC is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding GlaxoSmithKline PLC's research are outlined below:
| On 11th of April 2024 GlaxoSmithKline PLC paid $ 0.4061 per share dividend to its current shareholders | |
| Latest headline from aol.com: Senator slams drugmaker for seeming to skirt pledge to cap inhaler cost |
GlaxoSmithKline PLC Quarterly Good Will |
|
GlaxoSmithKline PLC uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in GlaxoSmithKline PLC ADR. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to GlaxoSmithKline PLC's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 31st of January 2024 Upcoming Quarterly Report | View | |
| 24th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 31st of January 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact GlaxoSmithKline PLC's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises GlaxoSmithKline PLC's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-07-29 | 2020-06-30 | 0.64 | 0.57 | -0.07 | 10 | ||
2016-02-03 | 2015-12-31 | 0.61 | 0.69 | 0.08 | 13 | ||
1995-02-07 | 1994-12-31 | 0.9 | 0.99 | 0.09 | 10 | ||
2023-07-26 | 2023-06-30 | 0.87 | 0.97 | 0.1 | 11 | ||
2004-10-28 | 2004-09-30 | 0.89 | 0.99 | 0.1 | 11 | ||
2023-02-01 | 2022-12-31 | 0.5 | 0.61 | 0.11 | 22 | ||
2003-07-23 | 2003-06-30 | 0.86 | 0.98 | 0.12 | 13 | ||
2003-04-30 | 2003-03-31 | 0.74 | 0.86 | 0.12 | 16 |
Know GlaxoSmithKline PLC's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as GlaxoSmithKline PLC is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading GlaxoSmithKline PLC ADR backward and forwards among themselves. GlaxoSmithKline PLC's institutional investor refers to the entity that pools money to purchase GlaxoSmithKline PLC's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Arrowstreet Capital Limited Partnership | 2023-12-31 | 4.8 M | Mondrian Investment Partners Ltd | 2023-12-31 | 4 M | Provident Trust Company | 2023-12-31 | 3.7 M | Equity Investment Corp | 2023-12-31 | 3.2 M | Eversept Partners, Llc | 2023-12-31 | 3 M | Renaissance Technologies Corp | 2023-12-31 | 2.8 M | Hotchkis & Wiley Capital Management Llc | 2023-12-31 | 2.7 M | Hsbc Holdings Plc | 2023-12-31 | 2.5 M | Wells Fargo & Co | 2023-12-31 | 2.5 M | Dodge & Cox | 2023-12-31 | 69 M | Fmr Inc | 2023-12-31 | 19.4 M |
GlaxoSmithKline PLC's market capitalization trends
The company currently falls under 'Large-Cap' category with a total capitalization of 88.69 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate GlaxoSmithKline PLC's market, we take the total number of its shares issued and multiply it by GlaxoSmithKline PLC's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
GlaxoSmithKline PLC's profitablity analysis
GlaxoSmithKline PLC's profitability indicators refer to fundamental financial ratios that showcase GlaxoSmithKline PLC's ability to generate income relative to its revenue or operating costs. If, let's say, GlaxoSmithKline PLC is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, GlaxoSmithKline PLC's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of GlaxoSmithKline PLC's profitability requires more research than a typical breakdown of GlaxoSmithKline PLC's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.13 | 0.21 | |
| Return On Capital Employed | 0.18 | 0.18 | |
| Return On Assets | 0.08 | 0.15 | |
| Return On Equity | 0.37 | 0.42 |
Determining GlaxoSmithKline PLC's profitability involves analyzing its financial statements and using various financial metrics to determine if GlaxoSmithKline PLC is a good buy. For example, gross profit margin measures GlaxoSmithKline PLC's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of GlaxoSmithKline PLC's profitability and make more informed investment decisions.
The data published in GlaxoSmithKline PLC's official financial statements usually reflect GlaxoSmithKline PLC's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of GlaxoSmithKline PLC ADR. For example, before you start analyzing numbers published by GlaxoSmithKline accountants, it's critical to develop an understanding of what GlaxoSmithKline PLC's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of GlaxoSmithKline PLC's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, GlaxoSmithKline PLC's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in GlaxoSmithKline PLC's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of GlaxoSmithKline PLC ADR. Please utilize our Beneish M Score to check the likelihood of GlaxoSmithKline PLC's management manipulating its earnings.
Evaluate GlaxoSmithKline PLC's management efficiency
GlaxoSmithKline PLC ADR has Return on Asset of 0.1006 % which means that on every $100 spent on assets, it made $0.1006 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.3878 %, implying that it generated $0.3878 on every 100 dollars invested. GlaxoSmithKline PLC's management efficiency ratios could be used to measure how well GlaxoSmithKline PLC manages its routine affairs as well as how well it operates its assets and liabilities. At this time, GlaxoSmithKline PLC's Return On Tangible Assets are quite stable compared to the past year. Return On Assets is expected to rise to 0.15 this year, although the value of Return On Capital Employed will most likely fall to 0.18. Change To Liabilities is expected to rise to about 596.5 M this year, although the value of Total Current Liabilities will most likely fall to about 11.2 B.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.29 | 2.26 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | (2.17) | (2.06) | |
| Enterprise Value Over EBITDA | 14.34 | 7.90 | |
| Price Book Value Ratio | 8.85 | 9.29 | |
| Enterprise Value Multiple | 14.34 | 7.90 | |
| Price Fair Value | 8.85 | 9.29 | |
| Enterprise Value | 133.2 B | 139.8 B |
The analysis of GlaxoSmithKline PLC's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze GlaxoSmithKline PLC's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of GlaxoSmithKline Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Dividend Yield 0.0347 | Forward Dividend Yield 0.0347 | Forward Dividend Rate 1.5 | Beta 0.268 |
Basic technical analysis of GlaxoSmithKline Stock
As of the 3rd of May, GlaxoSmithKline PLC retains the market risk adjusted performance of 0.2764, and Risk Adjusted Performance of 0.1116. GlaxoSmithKline PLC technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We are able to interpolate and collect nineteen technical drivers for GlaxoSmithKline PLC ADR, which can be compared to its competitors. Please check out GlaxoSmithKline PLC ADR coefficient of variation, as well as the relationship between the treynor ratio and semi variance to decide if GlaxoSmithKline PLC is priced fairly, providing market reflects its last-minute price of 43.35 per share. Given that GlaxoSmithKline PLC ADR has jensen alpha of 0.1388, we strongly advise you to confirm GlaxoSmithKline PLC ADR's regular market performance to make sure the company can sustain itself at a future point.Understand GlaxoSmithKline PLC's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing GlaxoSmithKline PLC's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1116 | |||
| Market Risk Adjusted Performance | 0.2764 | |||
| Mean Deviation | 0.7967 | |||
| Semi Deviation | 0.7288 | |||
| Downside Deviation | 0.9463 | |||
| Coefficient Of Variation | 597.23 | |||
| Standard Deviation | 1.06 | |||
| Variance | 1.12 | |||
| Information Ratio | 0.1153 | |||
| Jensen Alpha | 0.1388 | |||
| Total Risk Alpha | 0.0929 | |||
| Sortino Ratio | 0.1289 | |||
| Treynor Ratio | 0.2664 | |||
| Maximum Drawdown | 5.09 | |||
| Value At Risk | (1.49) | |||
| Potential Upside | 2.11 | |||
| Downside Variance | 0.8955 | |||
| Semi Variance | 0.5312 | |||
| Expected Short fall | (0.88) | |||
| Skewness | 0.3836 | |||
| Kurtosis | 0.366 |
| Risk Adjusted Performance | 0.1116 | |||
| Market Risk Adjusted Performance | 0.2764 | |||
| Mean Deviation | 0.7967 | |||
| Semi Deviation | 0.7288 | |||
| Downside Deviation | 0.9463 | |||
| Coefficient Of Variation | 597.23 | |||
| Standard Deviation | 1.06 | |||
| Variance | 1.12 | |||
| Information Ratio | 0.1153 | |||
| Jensen Alpha | 0.1388 | |||
| Total Risk Alpha | 0.0929 | |||
| Sortino Ratio | 0.1289 | |||
| Treynor Ratio | 0.2664 | |||
| Maximum Drawdown | 5.09 | |||
| Value At Risk | (1.49) | |||
| Potential Upside | 2.11 | |||
| Downside Variance | 0.8955 | |||
| Semi Variance | 0.5312 | |||
| Expected Short fall | (0.88) | |||
| Skewness | 0.3836 | |||
| Kurtosis | 0.366 |
Consider GlaxoSmithKline PLC's intraday indicators
GlaxoSmithKline PLC intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of GlaxoSmithKline PLC stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
GlaxoSmithKline PLC Corporate Filings
6K | 3rd of May 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 4th of April 2024 Other Reports | ViewVerify | |
F3 | 28th of March 2024 An amendment to the original Schedule 13D filing | ViewVerify |
GlaxoSmithKline Stock media impact
Far too much social signal, news, headlines, and media speculation about GlaxoSmithKline PLC that are available to investors today. That information is available publicly through GlaxoSmithKline media outlets and privately through word of mouth or via GlaxoSmithKline internal channels. However, regardless of the origin, that massive amount of GlaxoSmithKline data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of GlaxoSmithKline PLC news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of GlaxoSmithKline PLC relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to GlaxoSmithKline PLC's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive GlaxoSmithKline PLC alpha.
GlaxoSmithKline PLC Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards GlaxoSmithKline PLC can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
GlaxoSmithKline PLC ADR Historical Investor Sentiment
Investor biases related to GlaxoSmithKline PLC's public news can be used to forecast risks associated with an investment in GlaxoSmithKline. The trend in average sentiment can be used to explain how an investor holding GlaxoSmithKline can time the market purely based on public headlines and social activities around GlaxoSmithKline PLC ADR. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
GlaxoSmithKline PLC's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for GlaxoSmithKline PLC and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average GlaxoSmithKline PLC news discussions. The higher the estimate score, the more favorable the investor's outlook on GlaxoSmithKline PLC.
Be your own money manager
Our tools can tell you how much better you can do entering a position in GlaxoSmithKline PLC without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Money Flow Index Now
Money Flow IndexDetermine momentum by analyzing Money Flow Index and other technical indicators |
| All Next | Launch Module |
GlaxoSmithKline PLC Corporate Directors
GlaxoSmithKline PLC corporate directors refer to members of a GlaxoSmithKline PLC board of directors. The board of directors generally takes responsibility for the GlaxoSmithKline PLC's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of GlaxoSmithKline PLC's board members must vote for the resolution. The GlaxoSmithKline PLC board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Vindi Banga | Senior Independent Non-Executive Director | Profile | |
| Lynn Elsenhans | Independent Non-Executive Director | Profile | |
| Daniel Podolsky | Non-Executive Independent Director | Profile | |
| Harry Dietz | Non-Executive Independent Director, Scientific and Medical Expert | Profile |
How to buy GlaxoSmithKline Stock?
To provide specific investment advice or recommendations on GlaxoSmithKline PLC ADR stock, we recommend investors consider the following general factors when evaluating GlaxoSmithKline PLC ADR. This will help you to make an informed decision on whether to include GlaxoSmithKline PLC in one of your diversified portfolios:- Examine GlaxoSmithKline PLC's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research GlaxoSmithKline PLC's leadership team and their track record. Good management can help GlaxoSmithKline PLC navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact GlaxoSmithKline PLC's business and its evolving consumer preferences.
- Compare GlaxoSmithKline PLC's performance and market position to its competitors. Analyze how GlaxoSmithKline PLC is positioned in terms of product offerings, innovation, and market share.
- Check if GlaxoSmithKline PLC pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about GlaxoSmithKline PLC's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in GlaxoSmithKline PLC ADR stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if GlaxoSmithKline PLC ADR is a good investment.
Already Invested in GlaxoSmithKline PLC ADR?
The danger of trading GlaxoSmithKline PLC ADR is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of GlaxoSmithKline PLC is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than GlaxoSmithKline PLC. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile GlaxoSmithKline PLC ADR is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for GlaxoSmithKline Stock analysis
When running GlaxoSmithKline PLC's price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Stocks Directory Find actively traded stocks across global markets |
Is GlaxoSmithKline PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.30) | Dividend Share 0.59 | Earnings Share 2.72 | Revenue Per Share 15.15 | Quarterly Revenue Growth 0.059 |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between GlaxoSmithKline PLC's value and its price, as these two are different measures arrived at by various means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.